Roche’s alzheimer’s drug clears plaques in 28 weeks, faces 2028 test to slow memory loss

Roche’s experimental Alzheimer’s drug, trontinemab, has cleared harmful protein deposits from the brains of nine out of 10 patients within read more...

Read full coverage on TraceNews